P124 Long-term safety of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA study

2013 ◽  
Vol 12 (6) ◽  
pp. 178
Author(s):  
S Nilsson ◽  
A.J. Schrader ◽  
J. Kliment ◽  
A. Solberg ◽  
L. Franzén ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastases ◽  
Castration Resistant Prostate Cancer ◽  
Phase 3 ◽  
Castration Resistant ◽  
Radium 223

scholarly journals Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial

2018 ◽  
Vol 73 (3) ◽  
pp. 427-435 ◽  
Author(s):  
Christopher C. Parker ◽  
Robert E. Coleman ◽  
Oliver Sartor ◽  
Nicholas J. Vogelzang ◽  
David Bottomley ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastases ◽  
Castration Resistant Prostate Cancer ◽  
Phase 3 ◽  
Cancer Trial ◽  
Castration Resistant ◽  
Radium 223
Sign in / Sign up

Export Citation Format

Share Document